The European launch of the 60-minute Xpert HPV test is underway. The IVD molecular diagnostic assay runs on Cepheid's (CPHD) GeneXpert System.
The test targets the E6 and E7 oncogenes of 14 cancer-related HPV types while specifically detecting the high-risk types 16 and 18/45.
HPV types 16 and 18 are associated with 71% of cervical cancer cases while type 45 is tied to 6% of additional cases.
Consensus estimates for Q1 and Q2 are a loss of $0.17/share on revenues of $105M and a loss of $0.06/share on revenues of $111M, respectively.
Consensus estimates for 2014 and 2015 are a loss of $0.24/share on revenues of $457.6M and earnings of $0.06/share on revenues of $533.2M, respectively.
348 mutual funds have positions, down from 377 a year earlier.